Browse our anti-ESM1 (ESM1) Antibodies

Mouse (Murine) Endothelial Cell-Specific Molecule 1 (ESM1) interaction partners

1. Data from murine model indicate that NGFR plays an important role in the pathogenesis and progression of oral squamous cell carcinoma via regulation of ESM1.

2. glomerular-derived Esm-1 as a potential non-invasive biomarker of diabetic nephropathy

3. Results reveal a novel pathway for endocan in the control of tumor growth, which involves inflammatory cells of the innate immunity.

4. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing VEGF bioavailability.

5. This study shows endocan can elicit severe inflammatory responses and inhibiting endocan release offers a potential strategy for treating sepsis.

6. endocan is normally present in the mouse brain and prior vascular perfusion with FITC may provide a useful tool for identify newly forming blood vessels.

7. Mouse endocan serum level was measured at a median of 0.96 ng/mL and 1.08 ng/mL in 129Sv mice and C57bl6, respectively.

8. A paracrine vasoregulatory pathway mediated by endothelial cell-derived ET-1 acting on the vascular smooth muscle ET(A) receptor.

9. Results suggest that endocan (ESM-1)is preferentially expressed in tumor endothelium in vivo and that its expression is regulated by tumor-derived factors.

Human Endothelial Cell-Specific Molecule 1 (ESM1) interaction partners

1. ESM-1 is significantly upregulated by the HIF-1alpha/VEGF pathway under intermittent hypoxia in endothelial cells, playing a critical role in enhancing adhesion between monocytes and endothelial cells.

2. Endocan values were not significantly correlated with the duration of CPB.

3. Further studies should investigate the prognostic value of the magnitude of postoperative Endocan concentration after cardiac surgery.

4. endocan values of less than 2.54ng/mL may be predictive of Acute Respiratory Distress Syndrome in severe sepsis and septic shock

5. serum levels were significantly lower in liver cirrhosis patients with cirrhotic cardiomyopathy

6. the results of the present study showed that the knockdown of ENDOCAN inhibited cell growth and induced cell apoptosis, which was accompanied by the inhibition of NF-kappaB activity in myeloid leukemia cells, indicating that ENDOCAN is a promising therapeutic target in leukemia.

7. serum pro-BNP and endocan levels were increased in hemodynamically significant patent ductus arteriosus infants before medical treatment and decreased in the days followed appropriate treatment

8. Serum endocan level shows a correlation with deteriorated aortic elastic properties, and could b a surrogate marker of escalating aortic stiffness in patients with newly diagnosed essential hypertension.

9. high Endocan level is associated with poor lung functions and severity of asthma in children

10. Blood endocan level is increased in polycystic ovary syndrome.

11. Study found significant differences in median (interquartile) endocan serum level in women with intrauterine growth restriction (IUGR) and control groups Endocan is likely involved in the pathogenesis of IUGR in pregnant women and possibly is a useful marker of endothelial dysfunction in these cases.

12. Elevated circulating endocan levels are associated with reduced lung ventilation function in COPD patients and those with acute exacerbation of COPD.

13. Endocan levels were associated with the development of Ventilator-Associated Pneumonia.

14. Serum endocan can correlate with erectile dysfunction (ED) severity and carotid intima-media thickness. In addition, it has a predictive value for cardiovascular risk in ED patients.

15. endocan levels are higher in patients who require mechanical ventilation in severe sepsis

16. Results show that aerum ESM-1 levels were significantly higher in the idiopathic sudden sensorineural hearing loss group than the control group which may confirm endothelial dysfunction involvement.

17. suggest that measurement of endocan level may help clinicians to predict the development of coronary collateral circulation in patients with stable coronary artery disease

18. suggest that serum ESM-1 level may be a novel endothelial dysfunction biomarker

19. Plasma ESM-1 levels are decreased during pregnancy and increased in early- and late-onset preeclampsia. The source of ESM-1 is probably not the placenta, but most likely maternal endothelial cells.

20. Serial endocan concentration meets the major requirements for predicting outcome in patients with severe sepsis. An assay of endocan concentration may be a good prognostic biomarker in the clinic for severe sepsis.